PersistenceMarketResearch states that the global osteoporosis drugs market will witness a CAGR of over 4.5% between 2020 and 2030.
Market Snapshot
The very first choice for osteoporosis are bisphosphonates. They are inclusive of Alendronate (Fosamax) – to be administered weekly; Risedronate (Actonel) – to be administered monthly or weekly; Ibandronate (Boniva) – quarterly intravenous (IV) infusion or monthly; and Zoledronic acid (Reclast), a yearly IV infusion; and denosumab (Xgeva, Prolia). The present-day research states that on not adhering to the prescribed intake of this drug, there could be a higher risk to spinal fractures. This factor is bound to go well with the osteoporosis drugs market in the years to come.
Plus, these days, intravenous bisphosphonates are preferred to the ones in pill form as they do not upset the stomach.
Going Deeper
Apart from bisphosphonates, the other products used as osteoporosis drugs include calcitonin, parathyroid hormone therapy, SERM (Selective Estrogen Inhibitors Modulator), and rank ligand inhibitors. The drugs that help in bone-building include Romosozumab (Evenity), Abaloparatide (Tymlos), and Teriparadite (Forteo). They work wonders for the ones who are subject to osteoporosis due to steroids, or those who had fractures, or those who have lower bone density.
Region-wise
North America holds the largest market share. This could be reasoned with hoards of collaborations being worked upon by companies for enhancing the research capabilities. Europe is second-seeded. The Asia-Pacific is expected to grow at the fastest rate between 2020 and 2030 due to companies making relentless efforts in commercializing generic and branded therapeutics, that too, taking affordability into consideration.
Competitive Landscape
The key market participants include Merck & Co., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novo Nordisk, Pfizer Inc., Amgen Inc., and Novartis International AG. Raloxifene from Dr. Reddy’s has been received very well for treating osteoporosis. DUAVEE from Pfizer Inc. comes across as a conjugated estrogen to treat/prevent post-menopausal osteoporosis. Also, Laboratorios Farmacéuticos Rovi, S.A. (ROVI), since Apr 2019, started marketing Teva Pharmaceuticals’ Tetridar for treating adults suffering from osteoporosis.To Know More about Report @ https://bit.ly/3bYEiYm
